AcquisitionOct 1, 2026Completed
🇺🇸 United States
AVAdvanced Vision Science, Inc.SPSpyGlass Pharma, Inc.
Healthcare › Medical Devices
Equity value$13MEquity value
AnnouncedOct 1, 2026
ConsiderationCash
StructureNot stated
RegionNorth America
Cross-borderNo
Contingent paymentNo
Part of this record is under review.
We found a possible difference from the filing on: Status. The figures shown are the ones currently published.
Overview
SpyGlass Pharma, Inc. agreed to acquire all outstanding shares of Advanced Vision Science, Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., for approximately $13 million in cash.
Deal rationale
The acquisition is intended to secure scalable commercial intraocular lens manufacturing capacity for SpyGlass Pharma’s BIM-IOL System and accelerate expansion of its lens portfolio.
AI-generated from the SEC filingCompletedHealthcare › Medical DevicesUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $13M | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
None listed
Sell-side
MHMTS Health Partners
Parties
Target
AVAdvanced Vision Science, Inc.
- Headquarters
- United States
- Ticker
- —
Acquirer
SPSpyGlass Pharma, Inc.
- Headquarters
- United States
- Ticker
- —
Seller
SPSanten Pharmaceutical Co., Ltd.
- Headquarters
- —
- Ticker
- —